Arrowhead Pharmaceuticals Income Statement Analysis

Revenue, earnings, and profit margins in millions USD

Scroll to see more
Arrowhead Pharmaceuticals, Inc. income statement - Annual data in millions USD
BreakdownFY 2025FY 2024FY 2023FY 2022FY 2021FY 2020FY 2019FY 2018
Period EndingDec 2025Sep 2024Sep 2023Sep 2022Sep 2021Sep 2020Sep 2019Sep 2018
Revenue & Gross Profit
Revenue829.453.55240.74243.23138.2987.99168.8016.14
Cost of Revenue23.930.000.000.000.000.000.000.00
Gross Profit805.523.55240.74243.23138.2987.99168.800.00
Operating Expenses
Research & Development607.16491.19353.19289.30201.88128.8881.0552.97
Selling, General & Administrative123.94113.4490.93132.4485.4452.2826.5619.11
Operating Expenses707.17604.63445.74421.74287.32181.15107.6072.08
Operating Income98.35-601.08-205.00-178.51-149.04-93.1661.19-55.94
Other Income/Expense
Interest Income37.2922.7215.305.036.120.000.000.00
Interest Expense89.36-32.3518.330.000.000.000.000.00
Other Income/Expense-46.81-1.751.540.772.070.58-22.390.44
Income
Income Before Tax51.53-612.46-206.49-172.71-140.85-84.5568.15-54.45
Income Tax Expense21.42-2.772.783.790.000.000.170.00
Net Income-1.63-599.49-205.28-176.06-140.85-84.5567.97-54.45
Net Income - Continuous Operations-1.63-609.69-209.28-176.490.000.000.000.00
Net Income - Discontinued Operations0.000.000.000.000.000.000.000.00
EBITDA164.82-582.49-175.67-168.09-140.77-87.2272.59-51.24
EBIT98.35-601.08-188.17-178.51-149.04-93.1668.15-55.94
Depreciation & Amortization23.9318.601.6210.428.274.202.740.00
Earnings Per Share
Basic EPS--5.00-2.00-2.00-1.00-1.001.00-1.00
Diluted EPS--5.00-2.00-2.00-1.00-1.001.00-1.00
Basic Shares Outstanding133.76119.78107.31105.43103.75100.7293.8683.64
Diluted Shares Outstanding133.76119.78107.31105.43103.75100.7298.6183.64